John R Fischer

EQT, InTandem, Partners Group pursue neurology deals; KKR-backed healthcare company narrows focus with divestiture

Private equity goes bullish over neurology.

Treatments for neurological disorders draw PE interest: 5 deals

Archimed, EQT and Partners Group are among the PE firms investing in neurology-focused companies.

Archimed, KKR and Novo target medical genetics; untapped women’s health investments could generate $14bn in returns

Private equity bets on the pharma and life sciences sector.

Medical genetics: 5 PE-backed deals

Archimed, KKR and Novo Holdings are among the PE firms investing in pharma research, development and sales for genetic medicine.

Exclusive: InTandem buys RCM vendor manager Healthfuse

InTandem is acquiring Healthfuse from New Capital Partners, PE Hub can reveal.

Energy Capital Partners inks $26.6bn sale; Audax, EQT, NMS Capital pursue clinical trial deals; Last call for Deal of the Year nominations

ECP agrees to sell Calpine Corp to energy company Constellation for $26.6 billion.

PE firms target clinical trial companies: 7 acquisitions

Audax Private Equity, EQT and NMS Capital are among the PE firms pursuing deals and sales in the clinical trial sector.

Global healthcare PE deal value soared to $115bn, finds Bain & Company

The surge was propelled by an increase in large deals and greater interest in biopharma and healthcare IT, Nirad Jain said in an exclusive interview with PE Hub.

IK Partners, Montagu, WindRose invest in cardiology; Apollo expects 'hybrid' strategies to increase

Private equity bets on cardiology.

Cardiology ripe for PE consolidation: 5 deals that highlight the trend

Montagu Private Equity, Lee Equity Partners and Webster Equity Partners are among the PE firms investing in the cardiology market.